The outcome of physical symptoms with treatment of depression

Journal of General Internal Medicine
Teri GrecoKurt Kroenke

Abstract

This study examined the prevalence, impact on health-related quality of life (HRQoL), and outcome of physical symptoms in depressed patients during 9 months of antidepressant therapy. Open-label, randomized, intention-to-treat trial with enrollment occurring April through November 1999. Thirty-seven primary care clinics within a research network. Five hundred seventy-three depressed patients started on one of three selective serotonin reuptake inhibitors (SSRIs) by their primary care physician and who completed a baseline interview. Patients were randomized to receive fluoxetine, paroxetine, or sertraline. Outcomes assessed included physical symptoms, depression, and multiple domains of HRQoL. Prevalence of physical symptoms was determined at baseline and after 1, 3, 6, and 9 months of treatment. Stepwise linear regression models were used to determine the independent effects of physical symptoms and depression on HRQoL domains. Of the 14 physical symptoms assessed, 13 were present in at least a third to half of the patients at baseline. Each symptom showed the greatest improvement during the initial month of treatment. In contrast, depression continued to show gradual improvement over a 9-month period. Physical symptoms had a ...Continue Reading

References

Jan 1, 1992·Psychiatric Medicine
Feb 1, 1992·Journal of Clinical Epidemiology·M Von KorffK Saunders
Nov 1, 1991·The American Journal of Psychiatry·G E Simon, M VonKorff
Jan 1, 1985·Journal of Psychosomatic Research·K W Bridges, D P Goldberg
Feb 1, 1982·The American Journal of Medicine·W KatonG Rosen
Jan 1, 1982·The American Journal of Medicine·W KatonG Rosen
Oct 1, 1981·The British Journal of Psychiatry : the Journal of Mental Science·R J MathewM Mirabi
Aug 1, 1995·Medical Care·D O ClarkG E Simon
Dec 14, 1994·JAMA : the Journal of the American Medical Association·R L SpitzerJ G Johnson
Jul 1, 1993·Journal of Psychiatric Research·G E SimonM VonKorff
Oct 1, 1996·Archives of General Psychiatry·W KatonE Walker
Oct 28, 1999·The New England Journal of Medicine·G E SimonJ Ormel
Sep 15, 2001·Journal of General Internal Medicine·K KroenkeJ B Williams
Dec 26, 2001·JAMA : the Journal of the American Medical Association·K KroenkeM Weinberger
Mar 27, 2002·Psychosomatic Medicine·Kurt KroenkeJanet B W Williams
Dec 4, 2002·Psychosomatic Medicine·Lesley A AllenRobert L Woolfolk
Dec 11, 2002·JAMA : the Journal of the American Medical Association·Jürgen UnützerUNKNOWN IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment
Jun 28, 2003·International Journal of Methods in Psychiatric Research·Kurt Kroenke
Nov 12, 2003·Archives of Internal Medicine·Matthew J BairKurt Kroenke
Jan 30, 2004·Psychosomatic Medicine·Matthew J BairKurt Kroenke

❮ Previous
Next ❯

Citations

Jan 12, 2007·Journal of Urban Health : Bulletin of the New York Academy of Medicine·SangWoo TakChristine West
Nov 26, 2008·Journal of General Internal Medicine·Patrick O MonahanClaris Ojwang
Oct 28, 2005·The New England Journal of Medicine·J John Mann
Apr 14, 2006·Current Opinion in Psychiatry·Peter Henningsen, Bernd Löwe
Apr 12, 2008·Journal of Occupational and Environmental Medicine·Debra Lerner, Rachel Mosher Henke
Jan 19, 2012·Psychiatry and Clinical Neurosciences·Ching-I HungShuu-Jiun Wang
Jan 21, 2006·Journal of General Internal Medicine·Bernd LöweStefanie Wilke
Jul 1, 2006·Journal of General Internal Medicine·Jeffrey L Jackson, Kurt Kroenke
Oct 20, 2007·International Journal of Clinical Practice·V MaleticJ Russell
Apr 1, 2007·Neuropsychiatric Disease and Treatment·David J Goldstein
Oct 16, 2007·Primary Care Companion to the Journal of Clinical Psychiatry
Aug 31, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ching-Hua LinCheng-Chung Chen
Apr 1, 2006·Acta Neuropsychiatrica·Lana J WilliamsMichael Berk
Jul 10, 2004·Journal of General Internal Medicine·Wayne J Katon
Jan 1, 2007·International Journal of Psychiatry in Clinical Practice·Héctor J DueñasAdrian Vargas
Dec 4, 2013·Expert Opinion on Therapeutic Targets·Kanwaljit Chopra, Vipin Arora
Jun 21, 2014·Current Medical Research and Opinion·M FergusonS R Wisniewski
Apr 1, 2010·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Angela M DeVeaugh-GeissKurt Kroenke
Jul 19, 2011·General Hospital Psychiatry·Natalie Steinbrecher, Wolfgang Hiller
Feb 8, 2011·Comprehensive Psychiatry·Ka-Fai Chung, Kwok-Chu Tso
Jun 2, 2016·Iranian Red Crescent Medical Journal·Fatemeh AlijanihaSima Sadrai
Nov 4, 2008·La Presse médicale·Antoine Pelissolo
Apr 25, 2008·General Hospital Psychiatry·Bernd LöweKurt Kroenke
May 27, 2008·Journal of Psychosomatic Research·Monika MussellBernd Löwe
Oct 10, 2007·Journal of Cardiac Failure·David B BekelmanSydney M Dy
Jan 11, 2013·International Journal of Family Medicine·Kim KristiansenClaus Moe
Oct 30, 2007·Pharmacotherapy·Michael W Jann, Julian H Slade
Jun 6, 2015·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Diego NovickJosep Maria Haro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved